Autologous Protein Solution (APS)– the Biological symptom management of HIP osteoarthritis.
- Conditions
- Hip osteoarthritisMusculoskeletal - Osteoarthritis
- Registration Number
- ACTRN12619001101178
- Lead Sponsor
- .University of Melbourne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 10
(i)aged>40 years;
(ii)hip pain on most days in the last month;
(iii)X-ray confirmation of the diagnosis of hip osteoarthritis with Kellgren and Lawrence (KL) grade 2-3
(iv)A minimum pain score of 4 on an 11-point numeric rating scale for the last week having ceased all pain medications 5 days prior
(i)X-ray confirmation of the diagnosis with Kellgren and Lawrence (KL) grade 1 indicating questionable disease or grade 4 indicating severe disease;
(ii)Hip dysplasia or past Perthes disease or slipped upper femoral epiphysis;
(iii)Radiographic evidence of avascular necrosis
(iv)Hyaluronic acid injection in past 6 months, corticosteroid injection in past 3 months or autologous blood product in the past 12 months;
(v)Hip surgery on the affected side within the past 12 months;
(vi)systemic or inflammatory joint disease;
(vii)history of crystalline or neuropathic arthropathy;
(viii)plan for joint surgery in next 12 months;
(ix)other muscular, joint or neurological condition affecting lower limb function;
(x)needle phobia;
(xi)immunosuppression or acute infective processes;
(xii)cancer or other tumour-like lesions;
(xiii)bleeding disorder or receiving anti-coagulation therapy (at the discretion of the PI);
(xiv)any other medical condition precluding participation in the study including contraindication to MRI such as pregnancy;
(xv)Inability to understand written/spoken English.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method